Zai Lab Limited (HKG:9688)

Market Cap	27.37B
Revenue (ttm)	3.36B
Net Income (ttm)	-1.67B
Shares Out	n/a
EPS (ttm)	-15.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,102,100
Average Volume	15,927,755
Open	24.62
Previous Close	24.32
Day's Range	24.52 - 24.78
52-Week Range	15.50 - 35.50
Beta	1.04
RSI	40.61
Earnings Date	Nov 7, 2025

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1,869
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD